All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000817-20 | A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapo... | 2005-10-03 | due-trials |
| Reported results | 2004-002844-93 | A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodo... | 2007-03-01 | due-trials |
| Exempt, with results | 2009-016223-56 | An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma | 2013-10-21 | not-yet-due |
| Reported results | 2011-004151-39 | Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL) | 2015-07-22 | due-trials |
| Reported results | 2011-005738-20 | Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | 2017-02-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-004766-17 | Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) | 2021-02-17 | bad-data |
| Reported results | 2013-002254-70 | A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe P... | 2016-10-12 | due-trials |
| Reported results | 2013-003935-32 | A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ? 6 Months to < 18 Years Receiving Treatment with Opioids Ensayo fase I, ... | 2021-12-13 | due-trials |
| Reported results | 2014-000109-11 | A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety with the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate. | 2016-07-12 | due-trials |
| Reported results | 2014-000110-61 | An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients with Rheumatoid Arthritis on Concomitant Methotrexate | 2018-01-18 | due-trials |
| Reported results | 2015-001555-69 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) and Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in ... | 2018-10-04 | due-trials |
| Reported results | 2015-003887-34 | A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects with Moderate to Severe Parkinson’s Disease | 2017-12-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-000202-37 | A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) | 2022-04-07 | bad-data |
| Reported results | 2018-000998-72 | A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis | 2020-11-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-000469-19 | A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age w... | 2023-10-04 | bad-data |
| Ongoing | 2020-004537-20 | Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) | not-yet-due |